

FIG. 1A




FIG. 1B




FIG. 2A




FIG. 2B




FIG. 3




FIG.4




FIG. 5A-1




FIG. 5A-2




FIG. 5B




FIG. 6A

DAMGO + Naloxone

FIG. 6B




FIG. 6C




FIG. 7A-1




FIG. 7A-2




FIG. 7A-3






FIG. 7B-1




FIG. 7B-2




FIG. 7B-3




FIG. 7C-1




FIG. 7C-2




FIG. 7C-3

CaMKII

DAMGO



DAMGO




FIG. 8A-1




FIG. 8A-2




FIG. 8A-3




FIG. 8B-1




FIG. 8B-2




FIG. 8B-3




FIG. 9




FIG. 10

Specific binding (fmol/mg protein)




FIG. 11A




FIG. 11B




FIG.12






FIG. 13




FIG. 14

2




FIG. 15




FIG. 16




FIG. 17




FIG. 18A-1

FIG. 18A-2




FIG. 18B-1




FIG. 18B-2




FIG. 19A




FIG. 19B



DAMGO




FIG. 20A




FIG. 20B




FIG. 21A




FIG. 21B




FIG. 22






FIG. 23A




FIG. 23B

APPROVED

DRAFT

301/SS




FIG. 24A




FIG. 24B




FIG. 25




FIG. 26